Literature DB >> 23280155

Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.

Christopher J Valerio1, Benjamin E Schreiber, Clive E Handler, Christopher P Denton, John G Coghlan.   

Abstract

OBJECTIVE: To determine whether patients with systemic sclerosis (SSc) and borderline mean pulmonary artery pressure (PAP) at cardiac catheterization are more likely to develop pulmonary hypertension (PH) than those in whom pulmonary pressure is normal.
METHODS: Patients with SSc in whom PH and significant interstitial lung disease had been excluded at baseline were enrolled in our prospective cohort. Analysis of followup data identified patients who met prespecified criteria prompting repeat catheterization to reassess for possible PH. Using Kaplan-Meier, receiver operating characteristic, and Cox regression methods, we studied the development of PH and death.
RESULTS: Of 228 patients in this study, 86 had borderline mean PAP (21-24 mm Hg) at baseline. Following prespecified criteria, 76 patients underwent repeat catheterization, and 29 of these developed PH. Two cases were related to disease of the left side of the heart. The average mean PAP increased from baseline (20.2 mm Hg) to followup (24.3 mm Hg) (P<0.05 by Student's t-test). Patients with borderline mean PAP were more likely to develop PH than patients with mean PAP≤20 mm Hg (P<0.001 by log rank test, hazard ratio [HR] 3.7). A transpulmonary gradient (TPG)≥11 mm Hg at baseline also predicted PH (P<0.001 by log rank test, HR 7.9). Incident development of pulmonary arterial hypertension (PAH) was not benign, with a mortality of 18% within 3 years.
CONCLUSION: Our findings indicate that borderline mean PAP and an elevated TPG in patients with SSc predict progression to PH. These patients should be monitored closely for the development of PH. Our findings indicate that catheterization data are useful in patients considered at risk of PAH.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2013        PMID: 23280155     DOI: 10.1002/art.37838

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  38 in total

Review 1.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

2.  Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis.

Authors:  Keita Ninagawa; Masaru Kato; Hiroyuki Nakamura; Nobuya Abe; Michihito Kono; Yuichiro Fujieda; Kenji Oku; Shinsuke Yasuda; Hiroshi Ohira; Ichizo Tsujino; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2019-07-06       Impact factor: 2.631

3.  Altered synchrony of right ventricular contraction in borderline pulmonary hypertension.

Authors:  Bouchra Lamia; Jean-François Muir; Luis-Carlos Molano; Catherine Viacroze; Jacques Benichou; Philippe Bonnet; Jean Quieffin; Antoine Cuvelier; Robert Naeije
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-19       Impact factor: 2.357

4.  Clinical characterization and survival of patients with borderline elevation in pulmonary artery pressure.

Authors:  Gustavo A Heresi; Omar A Minai; Adriano R Tonelli; Jeffrey P Hammel; Samar Farha; Joseph G Parambil; Raed A Dweik
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

Review 5.  [Pulmonary hypertension in connective tissue disease].

Authors:  E I Schwarz; S Ulrich
Journal:  Z Rheumatol       Date:  2018-04       Impact factor: 1.372

6.  Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis.

Authors:  Sara Jaafar; Scott Visovatti; Amber Young; Suiyuan Huang; Paul Cronin; Dharshan Vummidi; Vallerie McLaughlin; Dinesh Khanna
Journal:  Eur Respir J       Date:  2019-08-22       Impact factor: 16.671

7.  Is early diagnosis of pulmonary arterial hypertension possible in inflammatory rheumatic diseases? Experience from a single center in Turkey.

Authors:  Ali Akdoğan; Sercan Okutucu; Levent Kılıç; Barış Kaya; Banu Evranos; Kudret Aytemir; Lütfi Çöplü; İhsan Ertenli; Meral Çalgüneri; Ali Oto; Lale Tokgözoğlu
Journal:  Eur J Rheumatol       Date:  2015-03-01

Review 8.  Evaluation and classification of pulmonary arterial hypertension.

Authors:  Sandeep Sahay
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

Review 9.  The role of imaging in pulmonary hypertension.

Authors:  Meenal Sharma; Andrew T Burns; Kelvin Yap; David L Prior
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

10.  The frequency of pulmonary hypertension in patients with juvenile scleroderma.

Authors:  Amra Adrovic; Funda Oztunc; Kenan Barut; Aida Koka; Refet Gojak; Sezgin Sahin; Tuncalp Demir; Ozgur Kasapcopur
Journal:  Bosn J Basic Med Sci       Date:  2015-08-22       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.